USANA Health Sciences (NYSE:USNA) Cut to C+ at TheStreet

TheStreet cut shares of USANA Health Sciences (NYSE:USNA) from a b- rating to a c+ rating in a report released on Thursday morning, TheStreetRatingsTable reports.

Several other research firms also recently weighed in on USNA. Pivotal Research reaffirmed a buy rating and issued a $75.00 price objective on shares of USANA Health Sciences in a report on Wednesday, July 3rd. Tigress Financial initiated coverage on shares of USANA Health Sciences in a report on Tuesday, April 16th. They issued a buy rating for the company. Sidoti downgraded shares of OMNOVA Solutions from a buy rating to a neutral rating and set a $10.00 price objective for the company. in a report on Wednesday, July 3rd. Finally, ValuEngine raised shares of Westpac Banking from a sell rating to a hold rating in a report on Wednesday, May 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $72.50.

USNA stock opened at $59.73 on Thursday. The firm has a market capitalization of $1.38 billion, a P/E ratio of 11.58 and a beta of 0.51. The business has a 50-day moving average of $71.74. USANA Health Sciences has a fifty-two week low of $58.30 and a fifty-two week high of $137.95.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.02. The business had revenue of $272.90 million during the quarter, compared to the consensus estimate of $272.20 million. USANA Health Sciences had a net margin of 10.38% and a return on equity of 29.51%. The company’s quarterly revenue was down 6.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.19 earnings per share. On average, equities analysts forecast that USANA Health Sciences will post 3.9 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Citigroup Inc. lifted its holdings in USANA Health Sciences by 20.0% in the 1st quarter. Citigroup Inc. now owns 30,271 shares of the company’s stock valued at $2,539,000 after acquiring an additional 5,047 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in USANA Health Sciences by 392.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,746 shares of the company’s stock valued at $1,955,000 after acquiring an additional 11,754 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new stake in USANA Health Sciences in the 4th quarter valued at about $34,000. Marshall Wace North America L.P. acquired a new stake in USANA Health Sciences in the 1st quarter valued at about $1,305,000. Finally, SG Americas Securities LLC acquired a new stake in USANA Health Sciences in the 1st quarter valued at about $193,000. 59.70% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: How to interpret the current ratio

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.